• LAST PRICE
    5.3629
  • TODAY'S CHANGE (%)
    Trending Up0.0629 (1.1868%)
  • Bid / Lots
    5.4000/ 1
  • Ask / Lots
    5.4700/ 4
  • Open / Previous Close
    5.3300 / 5.3000
  • Day Range
    Low 5.1500
    High 5.3680
  • 52 Week Range
    Low 4.4600
    High 12.4450
  • Volume
    32,130
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5.3
TimeVolumeSILO
09:34 ET18365.26
09:39 ET9505.28
09:41 ET6405.28
09:48 ET13985.2
09:54 ET4505.2
09:56 ET31935.24
10:01 ET8055.22
10:06 ET5005.22
10:08 ET3405.22
10:24 ET36685.18
10:28 ET2005.2
10:30 ET10005.1902
10:32 ET5415.2
10:42 ET2005.2
10:44 ET5805.2
10:46 ET1005.2
10:50 ET3005.2
10:51 ET3005.2
10:53 ET2505.3399
11:09 ET30005.33
11:31 ET1505.36
12:30 ET1005.3346
12:32 ET1255.368
12:45 ET1015.32
01:28 ET5255.28
01:46 ET2005.3629
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSILO
Silo Pharma Inc
16.1M
2.5x
---
United StatesIPIX
Innovation Pharmaceuticals Inc
16.3M
-2.0x
---
United StatesAXIM
Axim Biotechnologies Inc
16.5M
-0.8x
---
United StatesSYN
Synthetic Biologics Inc
15.6M
-0.9x
---
United StatesOTIC
Otonomy Inc
16.8M
-0.4x
---
United StatesAPRE
Aprea Therapeutics Inc
15.2M
-0.1x
---
As of 2022-10-07

Company Information

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company. It is focused on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Parkinson’s and other neurological disorders. It focuses on identifying assets to license and fund the research for the well-being of patients and the healthcare industry. It has entered into a license agreement with the University of Baltimore, Maryland, and has entered into a joint venture with Zylo Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for delivery of potential novel treatments. It has entered into a sponsored research agreement with Columbia University, pursuant to which it has been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds.

Contact Information

Headquarters
560 Sylvan Ave, Suite 3160ENGLEWOOD CLIFFS, NJ, United States 07632
Phone
718-400-9031
Fax
---

Executives

Chairman of the Board, President, Chief Compliance Officer
Eric Weisblum
Chief Financial Officer
Daniel Ryweck
Director
Wayne Linsley
Independent Director
Kevin Munoz
Independent Director
Jeff Pavell

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$16.1M
Revenue (TTM)
$72.1K
Shares Outstanding
3.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.17
EPS
$2.11
Book Value
$4.59
P/E Ratio
2.5x
Price/Sales (TTM)
222.9
Price/Cash Flow (TTM)
3.1x
Operating Margin
-3,366.46%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.